Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2012; 18(10): 1003-1008
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1003
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1003
Author | Diagnosis | Treatment | n | Tumor response (OR) | Complications (OR) | Local recurrence (OR) | Overall survival (OR) |
Zhou et al[47] | HCC | RFA | 744 | - | 0.29 (0.13-0.65) | 4.50 (2.45-8.27) | 0.60 (0.36- 1.01) (5 yr) |
resection | 667 | ||||||
Wu et al[50] | CLM | RFA | 273 | - | 0.32 (0.07-1.52) | 4.89 (1.73-13.87) | 0.41 (0.22-0.90) (5 yr) |
resection | 574 | ||||||
Bouza et al[63] | HCC | RFA | 396 | 1.10 (1.04-1.17) | Total: 2.55 (1.8-3.65) | 0.37 (0.23-0.59) | 1.24 (1.05-1.48) (4 yr) |
PEI | 391 | Major: 1.85 (0.68-5.01) |
- Citation: Ansari D, Andersson R. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol 2012; 18(10): 1003-1008
- URL: https://www.wjgnet.com/1007-9327/full/v18/i10/1003.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i10.1003